Skip to main content

Judge Fallon Denies New Bellwether Trials

Judge Fallon Denies New Bellwether Trials

Judge Fallon Denies New Bellwether Trials

Introduction

Judge Fallon presiding over Xarelto MDL 2592 also denied a motion for new bellwether trials for the plaintiffs who had lost to the defendants in the first two bellwethers trials. The judge stood by his decisions stating that they were made on the right grounds. The plaintiffs had filed the motions highlighting the fact that certain data was deemed inadmissible by the court to be a part of the trials as it included international information. The plaintiffs also emphasized that the jury was informed to consider the drug manufacturers were required to disclose only the FDA approved tests to the patients that clearly excluded the prothrombin time test, which is a part of international labels, but not FDA approved.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients

A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…

FDA Adds New Warnings on Long-Term Opioid Risks

Categories: Opioids

Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!